Navidea Biopharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Navidea Biopharmaceuticals, Inc.
Biocon subsidiary Syngene and Strides associate Stelis have entered a deal with the potential to change India’s vaccines and biologics landscape, as the former's growth plans are catapulted. Meanwhile, the Strides group gets to cut debt by selling a unit that made the ill-fated Sputnik Light COVID-19 vaccine and after Akston Biosciences terminated another COVID-19 vaccine alliance
Shin Nippon Biomedical Laboratories would take over migraine candidate STS101, now under FDA review. Blue Water Vaccines to pick up BPH drug from Veru.
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
Strides’ biopharma arm Stelis Biopharma has moved closer to approval in the EU and likely the US too for a biosimilar to Eli Lilly’s Forteo in FY23, following GMP certification for its manufacturing units. Meanwhile, merchant bankers have been appointed to evaluate strategic options to raise cash for Stelis.
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Macrophage Therapeutics
- Neoprobe Corp.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.